mesalamine 400 MG Delayed Release Oral Capsule

1 INDICATIONS AND USAGE Mesalamine delayed-release capsules are an aminosalicylate indicated for: Treatment of mildly to moderately active ulcerative colitis in patients 5 years of age and older. ( 1.1 ) Maintenance of remission of ulcerative colitis in adults. ( 1.2 ) 1.1 Treatment of Mildly to Moderately Active Ulcerative Colitis Mesalamine delayed-release capsules are indicated for the treatment of mildly to moderately active ulcerative colitis in patients 5 years of age and older. 1.2 Maintenance of Remission of Ulcerative Colitis Mesalamine delayed-release capsules are indicated for the maintenance of remission of ulcerative colitis in adults.

teva pharmaceuticals usa, inc.

FDA Reported Adverse Reactions
`[1] off label use` `[2] drug ineffective` `[3] nausea` `[4] fatigue` `[5] diarrhoea` `[6] dyspnoea` `[7] death` `[8] pain` `[9] pneumonia` `[10] vomiting`

4 years ago

CAPSULE WHITE Teva 5907

16 HOW SUPPLIED/STORAGE AND HANDLING

MESALAMINE delayed-release capsules are available as clear capsules imprinted with “TEVA” and “5907” on both the cap and the body in black ink. Each capsule contains four reddish-brown, film-coated round 100 mg

MESALAMINE tablets. NDC 0093-5907-86 Bottle of 180 capsules Store at 20º to 25ºC (68º to 77ºF) [See USP Controlled Room Temperature].

More pills like CAPSULE Teva 5907

DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site

mesalamine 400 MG Delayed Release Oral Capsule

FDA Reported Adverse Reactions [1] off label use [2] drug ineffective [3] nausea [4] fatigue [5] diarrhoea [6] dyspnoea [7] death [8] pain [9] pneumonia [10] vomiting

CAPSULE WHITE Teva 5907

More pills like CAPSULE Teva 5907

FDA Reported Adverse Reactions
`[1] off label use` `[2] drug ineffective` `[3] nausea` `[4] fatigue` `[5] diarrhoea` `[6] dyspnoea` `[7] death` `[8] pain` `[9] pneumonia` `[10] vomiting`